These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 31817134)

  • 21. Association Between Ustekinumab Trough Concentrations and Clinical, Biomarker, and Endoscopic Outcomes in Patients With Crohn's Disease.
    Battat R; Kopylov U; Bessissow T; Bitton A; Cohen A; Jain A; Martel M; Seidman E; Afif W
    Clin Gastroenterol Hepatol; 2017 Sep; 15(9):1427-1434.e2. PubMed ID: 28365485
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Real-world short-term effectiveness of ustekinumab in 305 patients with Crohn's disease: results from the ENEIDA registry.
    Iborra M; Beltrán B; Fernández-Clotet A; Gutiérrez A; Antolín B; Huguet JM; De Francisco R; Merino O; Carpio D; García-López S; Mesonero F; Navarro P; Ferreiro-Iglesias R; Carbajo AY; Rivero M; Gisbert JP; Piñero-Pérez MC; Monfort D; Bujanda L; García-Sepulcre MF; Martín-Cardona A; Cañete F; Taxonera C; Domènech E; Nos P;
    Aliment Pharmacol Ther; 2019 Aug; 50(3):278-288. PubMed ID: 31222872
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Long-Term Outcomes of Intravenous Ustekinumab Maintenance Treatment in Patients With Loss of Response to Subcutaneous Dosing.
    Argüelles-Arias F; Rodriguez González FJ; González Antuña J; Castro Laria L; Gutiérrez Martinez F; Alcaín Martinez G; Maldonado Pérez B; Camargo Camero R; Martos Van Dussen JV; Fernández Castañer A; Valdés Delgado T
    Inflamm Bowel Dis; 2024 Jul; ():. PubMed ID: 39082955
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Ustekinumab for Crohn's Disease: Results of the ICC Registry, a Nationwide Prospective Observational Cohort Study.
    Biemans VBC; van der Meulen-de Jong AE; van der Woude CJ; Löwenberg M; Dijkstra G; Oldenburg B; de Boer NKH; van der Marel S; Bodelier AGL; Jansen JM; Haans JJL; Theeuwen R; de Jong D; Pierik MJ; Hoentjen F
    J Crohns Colitis; 2020 Jan; 14(1):33-45. PubMed ID: 31219157
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Ustekinumab in pediatric patients with Crohn's disease: safety, and efficacy results from a multicenter retrospective study in China.
    Li P; Wang L; Tang Z; Wang Y; Liu Z; Ge W; Huang Y
    Front Pediatr; 2024; 12():1371322. PubMed ID: 38665375
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Real-world effectiveness and safety of ustekinumab induction therapy for Korean patients with Crohn's disease: a KASID prospective multicenter study.
    Oh K; Hong HS; Ham NS; Lee J; Park SH; Yang SK; Yoon H; Kim YS; Choi CH; Ye BD;
    Intest Res; 2023 Jan; 21(1):137-147. PubMed ID: 36751044
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Real-World Effectiveness and Safety of Ustekinumab in Elderly Crohn's Disease Patients.
    Garg R; Aggarwal M; Butler R; Achkar JP; Lashner B; Philpott J; Cohen B; Qazi T; Rieder F; Regueiro M; Click B
    Dig Dis Sci; 2022 Jul; 67(7):3138-3147. PubMed ID: 34160735
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Long-Term Real-World Effectiveness and Safety of Ustekinumab in Crohn's Disease Patients: The SUSTAIN Study.
    Chaparro M; Baston-Rey I; Fernández-Salgado E; González García J; Ramos L; Diz-Lois Palomares MT; Argüelles-Arias F; Iglesias Flores E; Cabello M; Rubio Iturria S; Núñez Ortiz A; Charro M; Ginard D; Dueñas Sadornil C; Merino Ochoa O; Busquets D; Iyo E; Gutiérrez Casbas A; Ramírez de la Piscina P; Boscá-Watts MM; Arroyo M; García MJ; Hinojosa E; Gordillo J; Martínez Montiel P; Velayos Jiménez B; Quílez Ivorra C; Vázquez Morón JM; María Huguet J; González-Lama Y; Muñagorri Santos AI; Amo VM; Martín-Arranz MD; Bermejo F; Martínez Cadilla J; Rubín de Célix C; Fradejas Salazar P; San Román AL; Jiménez N; García López S; Figuerola A; Jiménez I; Martínez Cerezo FJ; Taxonera C; Varela P; de Francisco R; Monfort D; Molina Arriero G; Hernández Camba A; García-Alonso FJ; Van Domselaar M; Pajares Villarroya R; Núñez A; Rodríguez Moranta F; Marín-Jiménez I; Robles Alonso V; Martín Rodríguez MDM; Camo-Monterde P; García Tercero I; Navarro Llavat M; Arias García L; Hervías Cruz D; Sulleiro S; Novella C; Vispo E; Barreiro-de Acosta M; Gisbert JP
    Inflamm Bowel Dis; 2022 Nov; 28(11):1725-1736. PubMed ID: 35166347
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy of Intravenous Ustekinumab Reinduction in Patients With Crohn's Disease With a Loss of Response.
    Heron V; Li Fraine S; Panaccione N; Restellini S; Germain P; Candido K; Bernstein CN; Bessissow T; Bitton A; Chauhan UK; Lakatos PL; Marshall JK; Michetti P; Seow CH; Rosenfeld G; Panaccione R; Afif W
    J Can Assoc Gastroenterol; 2022 Oct; 5(5):208-213. PubMed ID: 36196277
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Optimizing outcomes with maintenance IV UST in highly bio-exposed patients with IBD. Efficacy and adjusted regimen in real world.
    Mínguez A; Coello E; Garrido A; Ripoll P; Gomez M; Aguas M; Iborra M; Cerrillo E; Tortosa L; Bayarri V; Bueno N; Fernández MJ; Marqués R; Nos P; Bastida G
    Gastroenterol Hepatol; 2024 Sep; ():502253. PubMed ID: 39270973
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effectiveness and Safety of Ustekinumab for Ulcerative Colitis: A Brazilian Multicentric Observational Study.
    Parra RS; Chebli JMF; de Azevedo MFC; Chebli LA; Zabot GP; Cassol OS; de Sá Brito Fróes R; Santana GO; Lubini M; Magro DO; Imbrizi M; Moraes ACDS; Teixeira FV; Alves Junior AJT; Gasparetti Junior NLT; da Costa Ferreira S; Queiroz NSF; Kotze PG; Féres O
    Crohns Colitis 360; 2024 Apr; 6(2):otae023. PubMed ID: 38681979
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Real-world long-term effectiveness of ustekinumab in Crohn's disease: results from the ENEIDA registry.
    Iborra M; Beltrán B; Fernández-Clotet A; Iglesias-Flores E; Navarro P; Rivero M; Gutiérrez A; Sierra-Ausin M; Mesonero F; Ferreiro-Iglesias R; Hinojosa J; Calvet X; Sicilia B; González-Muñoza C; Antolín B; González-Vivo M; Carbajo AY; García-López S; Martín-Cardona A; Surís G; Martin-Arranz MD; de Francisco R; Cañete F; Domènech E; Nos P;
    Aliment Pharmacol Ther; 2020 Sep; 52(6):1017-1030. PubMed ID: 32770851
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparative Effectiveness of Ustekinumab Versus Adalimumab in Induction of Clinical Response and Remission in Crohn's Disease: Experience of a Real-World Cohort at a Tertiary Care Inflammatory Bowel Disease Referral Center.
    Ahmed Z; Venkata K; Zhang N; Malik TA
    Gastroenterology Res; 2019 Oct; 12(5):245-251. PubMed ID: 31636774
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Long-term Outcome of Risankizumab in Crohn's Disease: a Real-world GETAID Study.
    Fumery M; Caron B; Hébuterne X; Altwegg R; Roblin X; Stefanescu C; Meyer A; Nachury M; Laharie D; Le Berre C; Guillo L; Biron A; Caillo L; Buisson A; Nancey S; Uzzan M; Vuitton L; Gilletta C; Geyl S; Blain A; Kirchgesner J; Ah-Soune P; Duveau N; Vidon M; Abitbol V; Paupard T; Tran-Minh ML; Defrance A; Peyrin-Biroulet L
    Clin Gastroenterol Hepatol; 2024 Dec; 22(12):2451-2458.e1. PubMed ID: 38729389
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Predictive models assessing the response to ustekinumab highlight the value of therapeutic drug monitoring in Crohn's disease.
    Liefferinckx C; Hubert A; Thomas D; Bottieau J; Minsart C; Cremer A; Amininejad L; Vallée F; Toubeau JF; Franchimont D
    Dig Liver Dis; 2023 Mar; 55(3):366-372. PubMed ID: 35977875
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effectiveness and safety of ustekinumab in bio-naïve Crohn's disease patients: a multicentre observational retrospective study.
    Teresa VD; Rául OM; Marisa I; Claudia HG; Esteban FV; Luigi M; Mª Mar MR; Lilyan KC; Luisa CP; Ángel PD; Raquel VL; Noemí MM; Benito VJ; Marta LS; Beatriz LC; Francisco MG; Pau GÁ; Federico AA
    Therap Adv Gastroenterol; 2023; 16():17562848231153560. PubMed ID: 36777363
    [TBL] [Abstract][Full Text] [Related]  

  • 37. USTEKINUMAB IN CROHN'S DISEASE MANAGEMENT: A BRAZILIAN OBSERVATIONAL STUDY.
    Castro PCS; Magro DO; Nones RB; Furlan TK; Miranda EF; Kotze PG
    Arq Gastroenterol; 2022; 59(4):501-507. PubMed ID: 36515346
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Rates, predictive factors and effectiveness of ustekinumab intensification to 4- or 6-weekly intervals in Crohn's disease.
    Derikx LAAP; Plevris N; Su S; Gros B; Lyons M; Siakavellas SI; Constantine-Cooke N; Jenkinson P; O'Hare C; Noble C; Arnott ID; Jones GR; Lees CW
    Dig Liver Dis; 2023 Aug; 55(8):1034-1041. PubMed ID: 36283944
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical effectiveness and safety of ustekinumab in youth with refractory inflammatory bowel disease: A retrospective cohort study.
    Alhadab A; Almarhoon A; AlAlwan A; Hammo A
    Saudi J Gastroenterol; 2024 Apr; ():. PubMed ID: 38597337
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prospective observational study on Stelara (ustekinumab) assessing effectiveness in Crohn's disease (PROSE): a 16-week follow-up.
    Forss A; Clements M; Myrelid P; Strid H; Söderman C; Wagner A; Andersson D; Hjelm F; ; Olén O; Ludvigsson JF; Halfvarson J
    Scand J Gastroenterol; 2021 Jun; 56(6):680-686. PubMed ID: 33794731
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.